Advertisement

Advertisement

ESMO Breast Cancer Virtual Congress 2021

Breast Cancer

Abemaciclib-Associated Adverse Events: Safety Analysis of monarchE

Treatment with abemaciclib, an orally available inhibitor of CDK4/6, has been associated with venous thromboembolic events (VTE), elevated aminotransferases (EAT), and interstitial lung disease (ILD)....

Breast Cancer
Immunotherapy

Cardiac Safety, Efficacy of Neoadjuvant Pertuzumab/Trastuzumab for Early-Stage HER2-Positive Breast Cancer

Long-term cardiac safety and efficacy have been confirmed for the combination of pertuzumab plus trastuzumab in patients with early-stage HER2-positive breast cancer, according to the final analysis o...

Breast Cancer

Long-Term Follow-up of Premenopausal Patients With Estrogen Receptor–Positive Breast Cancer: Goserelin and Tamoxifen

A 20-year follow-up of premenopausal patients with estrogen receptor–positive breast cancer and stratification by the molecular 70-gene risk signature suggested that patients at high risk of distant d...

Breast Cancer
Immunotherapy
Symptom Management

Incidence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan-nxki in Patients With HER2-Positive Metastatic Breast Cancer

Drug-related interstitial lung disease occurred in less than 16% of patients with HER2-positive metastatic breast cancer following treatment with trastuzumab deruxtecan-nxki (T-DXd) at the approved do...

Breast Cancer
Immunotherapy

Atezolizumab/Carboplatin as Immune Induction in Patients With Metastatic Invasive Lobular Breast Cancer

First results from the phase II GELATO study evaluating atezolizumab plus carboplatin presented at the ESMO Breast Cancer Virtual Congress 2021 demonstrated clinical benefit in patients with metastati...

Breast Cancer
Immunotherapy

Long-Term Analysis of Short-HER Trial Reported: Shorter Duration of Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer

Long-term analysis of the Short-HER trial showed that 9 weeks of adjuvant trastuzumab conveyed benefits comparable to a 1-year course in patients with early HER2-positive breast cancer deemed to be at...

Breast Cancer

Biomarker Analysis of the KAITLIN Trial: No Subgroup Benefits More From T-DM1 Plus Chemotherapy

In the phase III KAITLIN trial, replacing adjuvant taxane and trastuzumab with ado-trastuzumab emtansine (T-DM1) did not result in a significant improvement in invasive disease-free survival in the no...

Breast Cancer

Evolution to HER2-Low Breast Cancer: Investigating Potential Therapeutics

The finding that breast tumors can evolve to express low HER2 potentially increases the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate ther...

Advertisement

Advertisement



Advertisement